Диссертация (1154718), страница 17
Текст из файла (страница 17)
Predictors of survival after deep114vein thrombosis and pulmonary embolism: a population-based, cohort study. //Archives of internal medicine. 1999. № 5 (159). C. 445–53.75. Heit J.A., Spencer F.A., White R.H. The epidemiology of venousthromboembolism. // Journal of thrombosis and thrombolysis. 2016. № 1 (41). C.3–14.76. Hess K., Alzahrani S.H., Mathai M. [et al.].
A novel mechanism forhypofibrinolysis in diabetes: the role of complement C3. // Diabetologia. 2012. №4 (55). C. 1103–13.77. Higaki S., Nakano K., Onaka S. [et al.]. Clinical significance of measuringblood coagulation factor XIIIA regularly and continuously in patients with Crohn’sdisease // Journal of Gastroenterology and Hepatology. 2006. № 0 (0). C.060606032707070–???78. Hilhorst M., Winckers K., Wilde B.
[et al.]. Patients with AntineutrophilCytoplasmic Antibodies Associated Vasculitis in Remission Are Hypercoagulable// The Journal of Rheumatology. 2013. № 12 (40). C. 2042–2046.79. Hillarp A., Zöller B., Svensson P.J. [et al.]. The 20210 A allele of theprothrombin gene is a common risk factor among Swedish outpatients withverified deep venous thrombosis. // Thrombosis and haemostasis. 1997.
№ 3 (78).C. 990–2.80. Hoppe B., Häupl T., Skapenko A. [et al.]. Fibrinogen and factor XIII A-subunitgenotypes interactively influence C-reactive protein levels during inflammation //Annals of the Rheumatic Diseases. 2012. № 7 (71). C. 1163–1169.81. Howes J.-M., Richardson V.R., Smith K.A. [et al.]. Complement C3 is a novelplasma clot component with anti-fibrinolytic properties. // Diabetes & vasculardisease research. 2012.
№ 3 (9). C. 216–25.82. Huang W., Goldberg R.J., Anderson F.A. [et al.]. Secular Trends in Occurrenceof Acute Venous Thromboembolism: The Worcester VTE Study (1985-2009) //The American Journal of Medicine. 2014. № 9 (127). C. 829–839.e5.83. Iacoviello L., Castelnuovo A. Di, Knijff P. de [et al.]. Polymorphisms in theCoagulation Factor VII Gene and the Risk of Myocardial Infarction // New115England Journal of Medicine. 1998. № 2 (338). C. 79–85.84.
Jacques P.F., Bostom A.G., Williams R.R. [et al.]. Relation between folatestatus, a common mutation in methylenetetrahydrofolate reductase, and plasmahomocysteine concentrations. // Circulation. 1996. № 1 (93). C. 7–9.85. Jennette J.C., Falk R.J., Bacon P.A. [et al.]. 2012 Revised International ChapelHill Consensus Conference Nomenclature of Vasculitides // Arthritis &Rheumatism. 2013. № 1 (65). C. 1–11.86. Johannesdottir S.A., Horváth-Puhó E., Dekkers O.M. [et al.]. Use ofglucocorticoids and risk of venous thromboembolism: a nationwide populationbased case-control study. // JAMA internal medicine.
2013. № 9 (173). C. 743–52.87. Kambas K., Chrysanthopoulou A., Vassilopoulos D. [et al.]. Tissue factorexpression in neutrophil extracellular traps and neutrophil derived microparticles inantineutrophilcytoplasmicantibodyassociatedvasculitismaypromotethromboinflammation and the thrombophilic state associated with the disease. //Annals of the rheumatic diseases.
2014. № 10 (73). C. 1854–63.88. Kearon C., Akl E.A., Comerota A.J. [et al.]. Antithrombotic therapy for VTEdisease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: AmericanCollege of Chest Physicians Evidence-Based Clinical Practice Guidelines. // Chest.2012. № 2 Suppl (141). C. e419S–94S.89. Kim H., Ahn M., Choi S. [et al.]. Potential role of fibronectin inmicroglia/macrophage activation following cryoinjury in the rat brain: Animmunohistochemical study // Brain Research. 2013.
(1502). C. 11–19.90. Kluijtmans L.A., Kastelein J.J., Lindemans J. [et al.]. Thermolabilemethylenetetrahydrofolate reductase in coronary artery disease. // Circulation.1997. № 8 (96). C. 2573–7.91. Kohler H.P., Stickland M.H., Ossei-Gerning N. [et al.]. Association of acommon polymorphism in the factor XIII gene with myocardial infarction. //Thrombosis and haemostasis.
1998. № 1 (79). C. 8–13.92. Koster T., Rosendaal F.R., Ronde H. de [et al.]. Venous thrombosis due to pooranticoagulant response to activated protein C: Leiden Thrombophilia Study. //116Lancet (London, England). № 8886–8887 (342). C. 1503–6.93. Koton S., Schneider A.L.C., Rosamond W.D.
[et al.]. Stroke Incidence andMortality Trends in US Communities, 1987 to 2011 // JAMA. 2014. № 3 (312). C.259.94. Krishnaswamy G., Kelley J., Yerra L. [et al.]. Human endothelium as a sourceof multifunctional cytokines: molecular regulation and possible role in humandisease. // Journal of interferon & cytokine research : the official journal of theInternational Society for Interferon and Cytokine Research. 1999. № 2 (19).
C. 91–104.95. Kucher N., Schroeder V., Kohler H.P. Role of blood coagulation factor XIII inpatients with acute pulmonary embolism. Correlation of factor XIII antigen levelswith pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness //Thrombosis and Haemostasis.
2003. № 3 (90). C. 434–8.96. Kyrle P.A., Rosendaal F.R., Eichinger S. Risk assessment for recurrent venousthrombosis // The Lancet. 2010. № 9757 (376). C. 2032–2039.97. Lee J.J., Pope J.E. A meta-analysis of the risk of venous thromboembolism ininflammatory rheumatic diseases. // Arthritis research & therapy. 2014. № 5 (16).C. 435.98. Loof T.G., Morgelin M., Johansson L. [et al.]. Coagulation, an ancestral serineprotease cascade, exerts a novel function in early immune defense // Blood. 2011.№ 9 (118). C. 2589–2598.99. Lu J.X., Lu Z.Q., Zhang S. lan [et al.].
Polymorphism in Integrin ITGA2 isAssociated with Ischemic Stroke and Altered Serum Cholesterol in ChineseIndividuals // Balkan Medical Journal. 2014. № 1 (33). C. 55–59.100. Ma J., Stampfer M.J., Christensen B. [et al.]. A polymorphism of themethionine synthase gene: association with plasma folate, vitamin B12,homocyst(e)ine, and colorectal cancer risk. // Cancer epidemiology, biomarkers &prevention : a publication of the American Association for Cancer Research,cosponsored by the American Society of Preventive Oncology. 1999. № 9 (8).
C.825–9.117101. Ma T.-T., Huang Y.-M., Wang C. [et al.]. Coagulation and fibrinolysis indexprofile in patients with ANCA-associated vasculitis. // PloS one. 2014. № 5 (9). C.e97843.102. Magwenzi S.G., Ajjan R.A., Standeven K.F. Factor XIII supports plateletactivation and enhances thrombus formation by matrix proteins under flowconditions // Journal of Thrombosis and Haemostasis. 2011.
№ 4 (9). C. 820–833.103. Maino A., Rossio R., Cugno M. [et al.]. Hypereosinophilic syndrome, ChurgStrauss syndrome and parasitic diseases: possible links between eosinophilia andthrombosis. // Current vascular pharmacology. 2012. № 5 (10). C. 670–5.104. Mansfield M.W., Stickland M.H., Grant P.J. Plasminogen activator inhibitor1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulindependent diabetes.
// Thrombosis and haemostasis. 1995. № 4 (74). C. 1032–4.105.MargaglioneM.,D’AndreaG.,d’AddeddaM.[etal.].Themethylenetetrahydrofolate reductase TT677 genotype is associated with venousthrombosis independently of the coexistence of the FV Leiden and the prothrombinA20210 mutation. // Thrombosis and haemostasis.
1998. № 5 (79). C. 907–11.106. Martino R.R. De, Wallaert J.B., Rossi A.P. [et al.]. A meta-analysis ofanticoagulation for calf deep venous thrombosis. // Journal of vascular surgery.2012. № 1 (56). C. 228-37–7.107. Masuda E.M., Kistner R.L., Musikasinthorn C. [et al.]. The controversy ofmanaging calf vein thrombosis. // Journal of vascular surgery. 2012. № 2 (55). C.550–61.108. Meade T.W., Mellows S., Brozovic M. [et al.]. Haemostatic function andischaemic heart disease: principal results of the Northwick Park Heart Study.
//Lancet (London, England). 1986. № 8506 (2). C. 533–7.109. Merkel P.A., Chang Y., Pierangeli S.S. [et al.]. The prevalence and clinicalassociations of anticardiolipin antibodies in a large inception cohort of patientswith connective tissue diseases. // The American journal of medicine. 1996. № 6(101).
C. 576–83.110. Merkel P.A., Lo G.H., Holbrook J.T. [et al.]. Brief communication: high118incidence of venous thrombotic events among patients with Wegenergranulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT)Study. // Annals of internal medicine. 2005. № 8 (142). C. 620–6.111. Meyer M.F., Schnabel A., Schatz H. [et al.]. Lack of association betweenantiphospholipid antibodies and thrombocytopenia in patients with Wegener’sgranulomatosis.
// Seminars in arthritis and rheumatism. 2001. № 1 (31). C. 4–11.112. Millet A., Pederzoli-Ribeil M., Guillevin L. [et al.]. Antineutrophilcytoplasmic antibody-associated vasculitides: is it time to split up the group? //Annals of the Rheumatic Diseases. 2013.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
